Title: Analysing the dose to lacrimal glands in Carcinoma Nasopharynx: Is there a need for Ophthalmic prophylaxis?
Authors: Poornachandra Tejaswi, Jagannath Kunigal Puttaswamy, Lokesh Vishwanath, Poojar Sridhar, Vijay Calmuge Raghu, Saritha Sunny Pullan
DOI: https://dx.doi.org/10.18535/jmscr/v7i4.41
Abstract
References
Objective: To evaluate the relationship between lacrimal gland dose and ocular toxicity among the patients treated by Intensity Modulated Radiotherapy (IMRT) for Carcinoma Nasopharynx.
Material and Methods: 20 patients of Carcinoma Nasopharynxwere treated by IMRT techniqueto a curative dose of 70Gy. The lacrimal glands were contoured as Organ at risk (OARs) and the minimum dose, maximum dose, mean dose and V30 were evaluated. Radiation Therapy Oncology Group (RTOG) toxicity criteria was used to report on conjunctivitis, corneal ulceration and keratitis.
Results: The minimum dose, maximum dose and mean dose received by right lacrimal gland was 3.86Gy, 19.20Gy and 9.34Gy respectively and by left lacrimal gland was 3.84Gy, 23.02Gy and 9.94Gy respectively.
PTV volume (in cc) was evaluated. The minimum, maximum and mean PTV volumes were 193.9cc, 1444.6 cc and 550.6 cc respectively. In the patients who developed ocular toxicity, the mean PTV volume was 835.3cc.
The mean distance between lacrimal gland and PTV was found to be 0.6cm. 8 patients reported with Grade-I ocular toxicity. In all these patients, the lacrimal gland was found to be in close proximity to the PTV.V30 of left lacrimal gland was 11.87% and V30 of right lacrimal gland was 6.2% respectively in the patients who developed ocular toxicities.
Conclusion: This study documents that the mean dose and maximum dose to lacrimal gland is important for analysing the acute and late ocular toxicities. Hence, lacrimal gland should be contoured as Organ at risk in Carcinoma Nasopharynx and dose constraints should be given to minimise the toxicity and prevent Dry Eye Syndrome.
Keywords: Lacrimalgland, Nasopharynx, Keratitis sicca, Intensity Modulated Radiotherapy, Radiation Therapy Oncology Group.
- E. Whitnall, “Anatomy of the human orbit and accessory organs of vision”. Classics in Ophthalmology, Krieger, Huntington, NY, USA, 1979.
- A. Sullivan and L. E. Hann. “Hormonal influence on the secretory immune system of the eye: endocrine impact on the lacrimal gland accumulation and secretion of IgA and IgG”. Journal of Steroid Biochemistry. 1989; 34(1-6): 253-262.
- “Basic and clinical science course: orbit, eyelids and lacrimal system”. American academy of Ophthalmology. 2012; 7: 243-244.
- Obata, S. Yama Moto, H. Horiuchi and R. Machinami. Histopathologic study of human lacrimal gland: statistical analysis with special reference to aging. Ophthalmology. 1995; 102(4): 678-686.
- Tiwari S, Bhatt A, Nagamodi J, et al. Aqueous deficient dry eye syndrome post orbital radiotherapy: A 10-year retrospective study; Translational Vision Science and Technology. 2017; 6(3):19.
- The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop. 2007. Ocul Surf;5:75–92.
- G. Gensheimer, D. M. Kleinman, M. O. Gonzalez, et al. “Novel formulation of Glycerine 1% artificial tears extends tear film breakup time compared with Systane lubricant eye drops”. Journal of Ocular Pharmacology and Therapeutics, 2012; 28(5): 473-478
- Gregoire V, De Neve W, Eisbruch A, Lee N, Van den Weyngaert D, Van Gestel D. Intensity-modulated radiation therapy for head and neck carcinoma. Oncologist. 2007; 12: 555–564.
- Jeganathan VSE, Wirth A, MacManus MP. Ocular risks from orbital and periorbital radiation therapy: a critical review. Int J Radiat Oncol Biol Phys 2011; 79:650–9.
- Anne W Lee, Wai Tong Ng, Jian Ji Pan, et al. International guidelines for the delineation of the clinical target volume (CTV) for nasopharyngeal carcinoma, Radiotherapy and Oncology2018; 126(1): 25-36.
- Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31:1341–6.
- Bath SS, Sreeraman R, Dienes E. Beckett LA, Daly ME, Cui J. et al. Clinical-dosimetric relationship between lacrimal gland dose and ocular toxicity after intensity-modulated radiotherapy for sinonasal tumours. Br J Radiol 2013:86:20130459
- Bhandare N, Moiseenko V, Song WY, Morris CG, Bhatti MT, Mendenhall WM. Severe dry eye syndrome after radiotherapy for head and-neck tumours. Int J Radiat Oncol Biol Phys 2011; 82:1501–1508.